Search

GaOOH powders of submicron dimensions were synthesized through a simple, surfactant-free hydrothermal synthesis at pH values of 7 and 14. Sn and Cr at concentrations of 2 mol% and 1 mol%, respectively, were successfully incorporated into a GaOOH lattice at pH = 7. The synthesized powders were characterized through XRD, SEM, UV-Vis spectroscopy, XPS, and PL spectroscopy to untangle their structural, morphological, optical, elemental, and compositional- and defect-level analyses, respectively. All samples were individually tested for their in vitro anti-proliferation activities against three human cancer cell line profiles, namely, lung carcinoma (A549), colon adenocarcinoma (LoVo), and hepatocellular carcinoma (HuH-7). The samples showed obtrusive anti-proliferation activity against the three cancer line profiles. An apoptotic cell killing mechanism was found in the studied samples after a successful analysis of various staining assays and flowcytometric analyses in the A549 cancer cell profile. Cr loading at 1 mol% enhanced the cancer cell inhibition property of GaOOH against all cancer cells investigated. Also, the morphology and doping levels were observed to have a collective effect on the anti-proliferation activity of GaOOH with specificity in treating certain cancer cells.

Six different acylthiourea ligands (L1–L6) and their corresponding Ru(II)-p-cymene complexes (P1–P6) were designed to explore the structure–activity relationship of the complexes upon aliphatic chain and aromatic conjugation on the C- and N-terminals, respectively. The compounds were synthesized and adequately characterized using various analytical and spectroscopic techniques. The structures of P2–P6, solved using single crystal X-ray diffraction (XRD), confirmed the neutral monodentate coordination of the S atoms of the acylthiourea ligands to Ru(II) ions. In silico studies showed an increase of lipophilicity for the ligands with an increase in alkyl chain length or aromatic conjugation at the C- or N-terminal, respectively. Subsequently, mitogen-activated protein kinases (MAPK) were predicted as one of the primary targets for the complexes, which showed good binding affinity towards extracellular signal-regulated kinases (ERK1, ERK2 and ERK5), c-Jun N-terminal kinase (JNK) and p38 of the MAPK pathway. Henceforth, the complexes were tested for their anticancer activity in lung carcinoma (A549) and cisplatin-resistant lung carcinoma (cisA549R) cells and human umbilical vein epithelial normal cells (HUVEC). Interestingly, an increase in chain length or aromatic conjugation led to an increase in the activity of the complexes, with P5 (7.73 and 13.04 μM) and P6 (6.52 and 14.45 μM) showing the highest activity in A549 and cisA549R cells, which is better than the positive control, cisplatin (8.72 and 44.28 μM). Remarkably, we report the highest activity yet observed for complexes of the type [(η6-p-cymene)RuIICl2(S-acylthiourea)] in the tested cell lines. Aqueous solution studies showed that complexes P5 and P6 are rapidly hydrolyzed to produce solely aquated species that remained stable for 24 h. Staining assays and flow cytometric analyses of P5 and P6 in A549 cells revealed that the complexes induced apoptosis and arrested the cell cycle predominantly in the S phase. In vivo studies demonstrated the higher toxicity of cisplatin and a comparatively higher survival rate of mice injected with the most active complex P6. Histological analyses revealed that treatment with P6 at high doses of up to 8 mg kg−1 did not cause any palpable damage to the tested organs.

Ruthenium complexes with bioactive ligands are becoming promising substitutes for platinum complexes due to their precise action against various cancers. In the present study, the synthesis of three new arene Ru(ii) complexes containing new carbazole-based hydrazone ligands of general formula [(η6-benzene)Ru(L)Cl] (1-3; L = carbazolone benzhydrazone ligands), and their anticancer properties are described. The structural characterization of the ligands and their ruthenium complexes has been realized with the aid of elemental analysis, IR, UV-vis, NMR and HR-MS techniques. The molecular structures of all three complexes have been elucidated by single crystal X-ray crystallography and reveal the existence of pseudo-octahedral geometry around the ruthenium. The in vitro cancer cell growth inhibition property of the complexes against A549 (lung carcinoma), A2780 (ovarian adenocarcinoma) and non-cancerous 16HBE (human lung bronchial epithelium) cells were examined by MTT assay. All the complexes display good cytotoxicity towards both of these types of cancer cell compared to the standard drug cisplatin, with low IC50 values. Remarkably, complex 3, which contains an electron-donating substituent, induces a significant reduction of viability in A2780 cells. The inhibition capacity of the complexes towards A2780 cells proliferation was further confirmed using 5-ethynyl-2-deoxyuridine (EdU) assay via minimal DNA synthesis. The result of the acridine orange-ethidium bromide (AO-EB) fluorescent staining assay establishes that the cytotoxicity of the complexes was mediated by apoptosis in cancer cells. Furthermore, flow cytometry using Annexin V-FITC/propidium iodide (PI) double staining determines the quantitative discrimination of early apoptosis by the externalization of phosphatidylserine. In addition, cell cycle distribution indicates that the complexes block the cell cycle progression in the S-phase. The outcome of our investigation shows the promising scope and potency of tailored arene ruthenium complexes for precise cancer chemotherapy beyond platinum drugs.

Ruthenium complexes have attracted a surge of interest as anticancer drug candidates because of their low toxicity, diversity in mode-of-actions and non-cross drug resistance with conventional platinum-based agents. Despite remarkable advances, only a limited number of ruthenium complexes have been demonstrated to kill cancer cells and suppress metastasis simultaneously. Here, two organometallic tetranuclear Ru(II) arene complexes (Ru-1 and Ru-2) have been synthesized and evaluated for their in vitro activity against a panel of human cancer cell lines, including a cisplatin-resistant human lung cancer A549 cell line. A superior cytotoxic activity of the ruthenium complexes compared to cisplatin across distinct cell lines was observed. Further examination of the mechanism indicated that anticancer activity was accomplished by inducing apoptosis in cancer cells. In addition, we found that such compounds exhibited promising antimetastatic activity and reduced the invasiveness of cancer cells. Importantly, choosing Ru-1 as a target compound, a significantly enhanced safety profile relative to cisplatin in animals was validated, suggesting that these complexes can be used as promising candidates for cancer therapy and deserve further investigation.

In this study, we newly designed and synthesized a small library of ten structurally related C,N-cyclometalated ruthenium(II) complexes containing various pyridine-functionalized NHC ligand and chelating bipyridyl ligands (e.g., 2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine, and 1,10-phenanthroline (phen)). The complexes were well characterized by NMR, electrospray ionization-mass spectrometry, and single-crystal X-ray structure analyses. Among the new ruthenium(II) derivatives, we identified that the complex Ru8 bearing bulky moieties (i.e., phen and pentamethyl benzene) had the most potent cytotoxicity against all tested cancer cell lines, generating dose- and cell line-dependent IC50 values at the range of 3.3-15.0 μm. More significantly, Ru8 not only efficiently inhibited the metastasis process against invasion and migration of tumor cells but also exhibited potent antivascular effects by suppressing HUVEC cells migration and tube formation in vitro and blocking vessel generation in vivo (chicken chorioallantoic membrane model). In a metastatic A2780 tumor xenograft-bearing mouse model, administration of Ru8 outperformed antimetastatic agent NAMI-A and clinically approved cisplatin in terms of antitumor efficacy and inhibition of metastases to other organs. Overall, these data provided compelling evidence that the new cyclometalated ruthenium complex Ru8 is an attractive agent because of synergistically suppressing bulky tumors and metastasized tumor nudes. Therefore, the complex Ru8 deserves further investigations.

Takotsubo syndrome is a reversible, stress-induced transient systolic and diastolic dysfunction. It was first described as a characteristic ballooning of left ventricular apex which closely resembles a Japanese fishing pot. Here the authors present a case report of a 40-year-old female who was posted for elective tonsillectomy, that developed sudden de-saturation immediately post-intubation, examination showed bilateral extensive and ECG showed symmetrical T wave inversion in leads V1 to V6 and troponin I was positive. A diagnosis of Perioperative myocardial infarction was made and hence patient was taken for coronary angiogram which was found to be normal. The left ventricular angiogram showed a typical finding of apical ballooning. The patient was diagnosed to have- Takotsubo Syndrome. Treatment included tablet Torsemide, Ramipril and Metoprolol. She was discharged after 7 days as the vitals got normalised.

The infected diabetic wound ulcer is a significant problem for the diabetic patients, which leads to removal of affected foot site due to its delayed/non-healing tissues. The poly-microbial infections and active matrix metalloproteinases (MMP) are the significant influencing factors to delayed healing in diabetic mice. The main purposes of present investigation are to evaluation the targeted inactivation of MMP and avoid polymicrobial infections by using a combined therapeutic effect of metal chelating dipeptide (L-carnosine) and curcumin with the biocompatible silk protein hydrogel (L-car@cur/SF) dressing in the infected diabetic wound ulcer. The in vitro biological assay methods, such as, cell viability, anti-oxidant activity, anti-inflammatory macrophage cells and inhibition collagenase exhibited that the designed hydrogel matrix to be human cell compatible and could be accelerate for significant diabetic healing potential. The activation of cur/SF matrix by the L-carnosine was persuading the inactivation of matrix metalloproteinase-9 (MMP-9) through its potent chelating effects of Zn2+ ions from the MMP-9 active center. The L-car@cur/SF hydrogel was demonstrated for the effective MMP-9 inactivation and bacterial inhibition via in vivo mice wound site, which indorsed the diabetic wound healing efficiency in streptozotocin-tempted diabetic mice.

Tubercular meningitis (TBM) constitute 5% of all cases of extra pulmonary tuberculosis but a presentation leading to an ischemic stroke in a young adult is a rare clinical entity. In a case of TB vasculopathy, vasculitis, venous thrombosis and aneurysm may be the underlying events leading to a stroke. Stroke in TBM is seen in the tubercular zone which encompasses internal capsule, thalamus and caudate nucleus. Inflammatory mediators like TNF alpha, Interferon gamma and vascular endothelial growth factor have been implicated in the pathogenesis of arteritis. Imaging modalities like MRI show lesions which are usually bilateral in the territory of the perforating vessels. We report a case of 24 year old Asian male who presented with complaints of headache, projectile vomiting and altered sensorium. On examination his Glasgow Coma Scale (GCS) was 10/15, with left oculomotor and left facial nerve palsy, and hypotonia of all 4 limbs with bilateral plantar reflexes being mute. Contrast MRI of brain showed acute infarct, meningeal enhancement and basal exudates. He was started on Anti-tubercular therapy and steroids, but had a poor clinical outcome, due to his late presentation.

A suitable method for the synthesis of ruthenium(II) arene benzhydrazone complexes (1–6) of the general formula [(η6-arene)Ru(L)Cl] (arene-benzene or p-cymene; L-monobasic bidentate substituted 9-anthraldehyde benzhydrazone derivatives) has been described. The composition of the complexes has been established by elemental analysis, IR, UV-Vis, emission, NMR and ESI-MS spectral methods. The solid state molecular structure of a representative complex was determined by a single-crystal X-ray diffraction study and indicates the presence of pseudo-octahedral (piano stool) geometry. All the complexes have been thoroughly screened for their cytotoxicity against human cervical cancer cells (HeLa), human breast cancer cell line (MDA-MB-231) and human liver carcinoma cells (Hep G2) under in vitro conditions. Interestingly, the cytotoxic activity of complex 6 is much more potent than cisplatin with low IC50 values against all the cancer cell lines tested. Furthermore, the results of AO–EB, Hoechst 33258 and flow cytometry analyses reveal that these complexes induce cell death only through apoptosis. The comet assay has been employed to determine the extent of DNA fragmentation in cancer cells. A hemolysis assay with human erythrocytes demonstrated good blood biocompatibility of all the ruthenium(II) arene benzhydrazone complexes. These results highlight the strong possibility to develop highly active ruthenium complexes as anticancer agents.

The copper(II) complexes, [Cu(tscpy)(MeOH)](Cl) (1), [CuCl(mtscpy)] (2) and [CuCl(ptscpy)] (3) (where, Htscpy = pyridoxal thiosemicarbazone, Hmtscpy = pyridoxal N4-methyl thiosemicarbazone and Hptscpy = pyridoxal N4-phenylthiosemicarbazone) have been isolated and characterized by the aid of various analytical and spectral methods. The molecular structure of the cationic complex 1 and the neutral complex 3 were characterized by single crystal X-ray diffraction studies which revealed that the thiosemicarbazone ligands coordinated to the copper(II) centre as monoanionic tridentate (ONS−) forming five and six membered rings. The interaction of the new complexes with DNA has been explored using spectral and viscosity studies, indicating the complexes bind to DNA via partial intercalation. A predominantly hydrolytic cleavage of supercoiled pUC19 plasmid DNA was confirmed through an experiment performed in the presence of T4 ligase. Furthermore, the interactions of the complexes with serum albumin (BSA) were also investigated using fluorescence spectroscopic methods. The efficiency of the complexes in arresting the growth of human cervical cancer cells (HeLa), human breast cancer cell line (MCF-7) and human liver carcinoma cells (Hep G2) has also been studied along with the cell viability assay against the noncancerous NIH 3T3 mouse embryonic fibroblast cell lines under in vitro conditions. The cationic complex 1 has higher cytotoxic activity than the other two neutral complexes and cisplatin. AO–EB/DAPI staining assays, Annexin V-FITC and FACS analyses indicated that the complex 1 induces cell death only by apoptosis.

Background: Acute Myocardial Infarction is one of the leading causes of mortality and morbidity. Now there are a number of drugs for Thrombolysis but still Streptokinase is used in many of the centers because of the ease of availability and less cost. ST segment elevation resolution following thrombolysis is simple, non-invasive, accessible tool for the assessment of coronary reperfusion. Objective of the present study was to assess the efficacy of thrombolysis in Acute STEMI patients, with respect to resolution of ST-elevation on treatment with streptokinase and also to predict short term outcome during hospital stay in terms of adverse events and mortality.Methods: 60 Acute STEMI patients who had received thrombolytic therapy with streptokinase were studied in three groups namely Category A, Category B and Category C based on ST segment resolution after administration of thrombolytic therapy.Results: Of 60 patients, 9 patients (15%) had 70% ST resolution (complete STR).Conclusions: In the present study we conclude that the efficacy of IV streptokinase for thrombolysis in acute STEMI is 41.7%. Patients with no resolution of ST segment 90 minutes following thrombolysis associated with more frequent adverse events and increased mortality compare to partial and complete resolution group.

Background: Peripheral insensate neuropathy is one of the most common and forms of peripheral neuropathy. It is a preeminent cause for disability, foot ulcers, deformity and amputations in individuals who are at risk.Methods: A study was conducted in Mahatma Gandhi Medical College & Research Institute, Pondicherry, India in the year 2017-18, which included examination of 760 people of more than 30 years of age by random sampling method who was attending the outpatient clinic. The Semmes Weinstein monofilament was adopted to ascertain the presence of peripheral insensate neuropathy.Results: In present study, the prevalence of peripheral insensate neuropathy was 3.2%. As the height increased, the prevalence of peripheral insensate neuropathy increased, regardless of other independent risk factors like diabetes, hypertension, etc. The risk of the peripheral insensate neuropathy increases at a height of >171.5cm in males and at a height of >164.5cm in females.Conclusions: The authors confirm that body height is a significant and independent risk factor for peripheral insensate neuropathy, regardless of co-morbidities. Height as a guide, helps the health care professionals in identifying the people who are at risk for peripheral insensate neuropathy.

BACKGROUND: To find out whether there is any movement impairment difference in the normal mechanics of musculoskeletal system between low back pain (LBP) patients and healthy individuals, applying battery of movement control impairment (MCI) tests and also relationship of diagnosis to major clinical measures. METHODS: Design is a case–control study. Three-trained physiotherapists executed a test battery of six tests, for which the reliability has been shown to be acceptable. A total of 180 participants, ninety LBP patients and ninety age-matched normal individuals were recruited to participate in the study after given consent. The differences between the groups were analyzed using the effect size (ES) (d). Chi-square test with cross-tabulation was done to find out odds and risk ratios of the participants to represent or remain in the patient group. A correlation analysis was done between all the movement impairment tests and the clinical measures such as numerical pain rating scale, straight leg raising, pain location, flexion, and extension ROM and pain duration. RESULTS: This study results demonstrated that there is a difference between participants with and without back pain which could be a diagnostic and in clinical practice may help to identify subgroups of patients in LBP. Tests such as one leg standing, rocking backward, and prone knee flexion are negatively related to back pain functional outcome indicating more difficulty in function if they are positive with LBP patients. There was no difference found regarding the presence or positive test result between the acute and chronic pain patients. CONCLUSION: The present study concluded that there was a significant difference between patients with LBP and normal individuals without back pain in actively controlling the movements of the low back. The ES between patients with LBP and healthy controls in movement control is large. Moreover, the pain score and extension range of motion are not related to any of the MCI tests.